|1.||van der Kogel, Albert J: 4 articles (09/2013 - 07/2005)|
|2.||Raleigh, James A: 4 articles (09/2013 - 12/2002)|
|3.||Bussink, Johan: 4 articles (02/2007 - 09/2004)|
|4.||Ljungkvist, Anna S E: 3 articles (02/2007 - 07/2005)|
|5.||Kaanders, Johannes H A M: 3 articles (02/2007 - 07/2005)|
|6.||Ashcroft, Margaret: 1 article (09/2013)|
|7.||Jamin, Yann: 1 article (09/2013)|
|8.||Griffiths, John R: 1 article (09/2013)|
|9.||Baker, Lauren C J: 1 article (09/2013)|
|10.||Gilmour, Lesley D: 1 article (09/2013)|
02/01/1997 - "Quantification of CCI-103F labeling heterogeneity in canine solid tumors."
03/01/1994 - "CCI-103F labeling of hypoxic regions in tumors provides a nonradioactive method of detecting nitroimidazole adducts at the cellular level, and allows concurrent histologic examination. "
02/01/1994 - "Twelve dogs with spontaneous solid tumors were given intravenous CCI-103F, and tumor biopsies were taken at various times after injection. "
02/01/1994 - "ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation."
01/01/1992 - "We have now developed a rapid, quantitative, and non-radioactive enzyme linked immunosorbent assay for the binding of CCI-103F in biopsy samples of spontaneous canine tumors. "
03/01/2006 - "The second hypoxia marker, CCI-103F, and the proliferation marker BrdUrd were given at 4, 8 and 28 h after irradiation. "
01/01/1994 - "The scope and limitation of the ELISA for measuring the binding of CCI-103F is discussed and an example of the application of the ELISA to measuring changes in tumour hypoxia in canine patients undergoing fractionated radiation therapy is presented."
01/01/1994 - "The binding of CCI-103F is believed to reflect the presence of hypoxia in tumours. "
12/01/1990 - "Dynamic measurements of CCI-103F retention in tumours by MRS may provide a non-invasive probe for assessing tumour hypoxia."
08/01/1997 - "The hypoxia marker CCI-103F was studied in dogs bearing spontaneous solid tumors. "
|4.||Sarcoma (Soft Tissue Sarcoma)